6.00
-2.60%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fine Foods & Pharmaceuticals NTM SpA
Its shares trade on Borsa Italiana under the ticker FF.MI. It has been listed since 19 October 2016. In the fiscal year to 31 December 2025, it reported revenue of €252.1m and net income of €10.1m. At that date it held total assets of €280.0m and shareholders' equity of €134.2m.
Fine Foods & Pharmaceuticals N.T.M. The company is headquartered in Verdellino, Bergamo. The company went IPO on 2016-10-19. The company is specialized in the manufacturing of pharmaceutical products for third parties. The firm manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 19 Oct 2016
- Employees
- 748
- Website
- finefoods.it ↗
Leadership
Pay as last reported
- Mr. Marco EigenmannExecutive Chairman of the Board, Chief Executive Officer€611,828
- Mr. Pietro OrianiChief Executive Officer, Executive Director, since 2024€55,889
- Ms. Susanna PedrettiNon-Executive Lead Independent Director€32,500
- Mr. Marco CostagutaNon-Executive Director€20,000
- Mr. Giovanni EigenmannNon-Executive Director€110,732
- Mr. Adriano Pala CiurloNon-Executive Director€20,000
- Mr. Elena SaccoNon-Executive Director€17,752
- Mr. Paolo FerrarioNon-Executive Independent Director, since 2024€11,835
- Ms. Ada ImperadoreNon-Executive Independent Director€37,500
- Ms. Deborah VenturiniNon-Executive Independent Director€17,753
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 79
- Social
- 99
- Governance
- 62
- Direct emissions (scope 1)
- 7,264.51 t
- Energy emissions (scope 2)
- 1,087.68 t
- Women in the workforce
- 47%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company employs 748 full-time staff members in Verdellino.
- Three business segments cover Pharmaceuticals, Nutraceuticals, and Medical Devices.
- Medical Devices marked CE are available for licensing opportunities.
Weaknesses
- The company went public on 19 October 2016 via IPO.
- Headquarters are located in Verdellino, Bergamo, Italy.
- Manufacturing focuses on pharmaceutical products for third parties only.
Opportunities
- Pharmaceuticals segment includes powders, granules, and hard gelatin capsules.
- Nutraceuticals segment offers soluble and effervescent tablets and sticks.
- Medical devices cover gastrointestinal and weight management treatment areas.
Threats
- The sector is classified as Health Care life sciences.
- Products are packaged in sachets, blisters, and tablet bottles.
- Segment includes coated tablets and jars for distribution.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.